These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38897317)

  • 1. Duration of fever in children infected with influenza A(H1N1)pdm09, A(H3N2) or B virus and treated with baloxavir marboxil, oseltamivir, laninamivir, or zanamivir in Japan during the 2012-2013 and 2019-2020 influenza seasons.
    Sun Y; Wagatsuma K; Saito R; Sato I; Kawashima T; Saito T; Shimada Y; Ono Y; Kakuya F; Minato M; Kodo N; Suzuki E; Kitano A; Chon I; Phyu WW; Li J; Watanabe H
    Antiviral Res; 2024 Aug; 228():105938. PubMed ID: 38897317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Chon I; Wagatsuma K; Saito R; Tang JW; Isamu S; Suzuki E; Shirahige Y; Kawashima T; Minato M; Kodo N; Masaki H; Hamabata H; Yoshioka S; Ichikawa Y; Sun Y; Li J; Otoguto T; Watanabe H
    Antiviral Res; 2024 Sep; 229():105956. PubMed ID: 38969237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.
    Wagatsuma K; Saito R; Chon I; Phyu WW; Fujio K; Kawashima T; Sato I; Saito T; Minato M; Kodo N; Suzuki E; Ono Y; Masaki H; Shirahige Y; Kitano A; Hamabata H; Yuyang S; Jiaming L; Watanabe H
    Antiviral Res; 2022 May; 201():105310. PubMed ID: 35358601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of fever and symptoms in children after treatment with baloxavir marboxil and oseltamivir during the 2018-2019 season and detection of variant influenza a viruses with polymerase acidic subunit substitutions.
    Saito R; Osada H; Wagatsuma K; Chon I; Sato I; Kawashima T; Saito T; Kodo N; Ono Y; Shimada Y; Phyu W; Shobugawa Y
    Antiviral Res; 2020 Nov; 183():104951. PubMed ID: 32987032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of baloxavir marboxil against influenza in three seasons.
    Kakuya F; Okubo H; Fujiyasu H; Kurisawa MJ; Kinebuchi T
    Pediatr Int; 2022 Jan; 64(1):e15169. PubMed ID: 35790049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased symptom severity but unchanged neuraminidase inhibitor effectiveness for A(H1N1)pdm09 in the 2010-2011 season: comparison with the previous season and with seasonal A(H3N2) and B.
    Kawai N; Ikematsu H; Kawashima T; Maeda T; Ukai H; Hirotsu N; Iwaki N; Kashiwagi S
    Influenza Other Respir Viruses; 2013 May; 7(3):448-55. PubMed ID: 22897904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
    Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV
    Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro neuraminidase inhibitory concentration (IC
    Ikematsu H; Kawai N; Tani N; Chong Y; Bando T; Iwaki N; Kashiwagi S
    J Infect Chemother; 2020 Aug; 26(8):775-779. PubMed ID: 32249161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2015 Sep; 21(9):634-8. PubMed ID: 26096495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of the Frequency of Prescription and Pharmacy Revisits between Baloxavir Marboxil and Neuraminidase Inhibitors in Influenza-Infected Pediatric Patients during the 2019-2020 Influenza Season.
    Norikoshi Y; Ikeda T; Sasahara K; Hamada M; Torigoe E; Nagae M; Tashiro T; Horio F; Saruwatari J; Uchida Y; Anraku M
    Biol Pharm Bull; 2020; 43(12):1960-1965. PubMed ID: 33268716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological and clinical outcomes in outpatients treated with baloxavir or oseltamivir: A Japanese multicenter study in the 2019-2020 influenza season.
    Chong Y; Kawai N; Tani N; Bando T; Takasaki Y; Shindo S; Ikematsu H
    Antiviral Res; 2021 Aug; 192():105092. PubMed ID: 34052230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
    Ikematsu H; Kawai N; Kashiwagi S
    J Infect Chemother; 2012 Aug; 18(4):529-33. PubMed ID: 22370919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Takashita E; Meijer A; Lackenby A; Gubareva L; Rebelo-de-Andrade H; Besselaar T; Fry A; Gregory V; Leang SK; Huang W; Lo J; Pereyaslov D; Siqueira MM; Wang D; Mak GC; Zhang W; Daniels RS; Hurt AC; Tashiro M
    Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.
    Checkmahomed L; M'hamdi Z; Carbonneau J; Venable MC; Baz M; Abed Y; Boivin G
    J Infect Dis; 2020 Jan; 221(1):63-70. PubMed ID: 31419295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
    Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
    Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virological and clinical outcomes in outpatients treated with baloxavir or neuraminidase inhibitors for A(H3N2) influenza: A multicenter study of the 2022-2023 season.
    Goto T; Kawai N; Bando T; Takasaki Y; Shindo S; Tani N; Chong Y; Ikematsu H
    Antiviral Res; 2024 Apr; 224():105853. PubMed ID: 38430970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
    Samson M; Abed Y; Desrochers FM; Hamilton S; Luttick A; Tucker SP; Pryor MJ; Boivin G
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.